News

Kyorin Pharmaceutical has discovered and developed Imidafenacin. Kyorin Pharmaceutical grants Daiichi Sankyo rights to activities related to the development and marketing of Imidafenacin in Brazil, as per the

A series of data points including intermediates contents, purity, quality, stability and stereochemistry were collected and compared it with the national standard of Azithromycin API that were issued

Epratuzumab is a humanised monoclonal antibody targeting CD22 and modulating B-cell activity. The data supported the BILAG-based Combined Lupus Assessment (BICLA) as a clinically meaningful composite measure of

Cimzia is a PEGylated anti-TNF (Tumor Necrosis Factor), which has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Cimzia showed rapid and sustained

The PILLAR study [Protease Inhibitor TMC435 trial assessing the optimaL dose and duration as once daiLy Anti-viral Regimen] was a five-arm, global phase 2b randomized, double-blind, placebo controlled

Vismodegib is an investigational, oral, targeted medicine which selectively inhibits signaling in the Hedgehog pathway and treats adults with advanced basal cell carcinoma (BCC). The vismodegib application includes

Access said it will provide CobOral and CobaCyte siRNA formulations for evaluation of gene knockdown following oral and intravenous administration. RNAi is initiated by introducing small fragments of

A multi-center clinical study, whic involved 442 patients and used European Union (EU) approved cetuximab, led to the approval. In the trial, 222 patients received cetuximab plus cisplatin

The company which works for The National Institutes of Health (NIH), has been awarded funding from Capital Management for the NIH Integrated Research Facility (IRF) commissioning support project,